Schedule L-1 was inserted into the Drugs and Cosmetics Rules 1945 by GSR 780(E) of 10 November 2008 and applies to in-house pharmaceutical quality-control laboratories and to third-party drug-testing laboratories approved under Rule 150-A. It sets out the requirements for laboratory premises and layout, instrument qualification and calibration, standard operating procedures, chemicals and reference standards, analyst qualification and training, method verification, chain of custody for samples, OOS/OOT investigation, and retention of raw analytical data and records (typically five years or one year past expiry, whichever is later). Schedule L-1 sits alongside Schedule M — Schedule M covers the manufacturing side, Schedule L-1 governs the lab that releases the batch. State Licensing Authorities and CDSCO inspect Schedule L-1 compliance during GMP and Approved Testing Laboratory audits; findings commonly cover data integrity, incomplete instrument qualification, and weak OOS investigation. Related: CDSCO, Schedule M, 21 CFR 58, ICH Q2, data integrity, OOS.

Industries that live with this

Pharmaceutical

How V5 handles it

Score your compliance gap — then download the validation pack.

A guided self-assessment walks you against the regulator clauses that apply to your industry. The validation pack — IQ/OQ/PQ scripts, traceability matrix, risk assessment, intended-use statement — generates from the same evidence so you can hand it to an auditor on day one.

Document control with hard kiosk-level training enforcement.

Versioned SOPs are only useful if operators are actually trained on the current version. V5 enforces it at the kiosk.

QMS — quality engineered into every action, not bolted on.

Because V5 owns the operator action, the QMS sees the data the second it’s captured — not at the end of the shift.